anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NEW MATERIAL:A fredericamycin A derivative expressed by formula I (R is acyl; A is a group expressed by formula II or III). EXAMPLE:Di-n-lauroyltetrahydrofredericamycin A. USE:An antimicrobial agent and anticancer agent much more stable than fredericamycin A. PREPARATION:An antitumore antibiotic substance fredericamycin A, expressed by formula IV, and isolated from a culture of streptomyces grinseus FCRC-48 is catalytically reduced in the presence of H2 and a catalyst, e.g. Pd/C, and then partially oxidized to give tetrahydrofredericamycin A expressed by formula V, which is then acylated with a carboxylic acid expressed by the formula ROH or a reactive derivative thereof in a solvent, e.g. pyridine, if necessary in the presence of a condensing agent, e.g. dicyclohexylcarbodiimide, preferably at 0-4 deg.C for 2-48hr to afford the aimed compound expressed by formula I (A is a group expressed by formula II).
There is limited clinical trial experience with desvenlafaxine succinate overdosage in humans. However, desvenlafaxine is the major active metabolite of venlafaxine. Overdose experience reported with venlafaxine (the parent drug of desvenlafaxine extended-release tablets) is presented below; the identical information can be found in the Overdosage section of the venlafaxine package insert.

In postmarketing experience, overdose with venlafaxine (the parent drug of desvenlafaxine extended-release tablets) has occurred predominantly in combination with alcohol and/or other drugs. The most commonly reported events in overdosage include tachycardia, changes in level of consciousness (ranging from somnolence to coma), mydriasis, seizures, and vomiting. Electrocardiogram changes (e.g., prolongation of QT interval, bundle branch block, QRS prolongation), sinus and ventricular tachycardia, bradycardia, hypotension, rhabdomyolysis, vertigo, liver necrosis, serotonin syndrome, and death have been reported.

Published retrospective studies report that venlafaxine overdosage may be associated with an increased risk of fatal outcomes compared to that observed with SSRI antidepressant products, but lower than that for tricyclic antidepressants. Epidemiological studies have shown that venlafaxine-treated patients have a higher pre-existing burden of suicide risk factors than SSRI-treated patients. The extent to which the finding of an increased risk of fatal outcomes can be attributed to the toxicity of venlafaxine in overdosage, as opposed to some characteristic(s) of venlafaxine-treated patients, is not clear.
The HIV epidemic in the United States most severely affects men who have sex with men (MSM): 61% of all new infections occur in this population. Black MSM bear a disproportionate burden, with prevalence of 28%, in contrast to 19% in MSM overall. Black MSM undergo HIV testing less frequently than other MSM; are less likely to be aware that they are HIV infected; are more likely to experience delays in entry into HIV care; and are less likely to be prescribed antiretroviral therapy (ART) when eligible. These disparities are pronounced in substance-using MSM, as substance users are at elevated risk of late diagnosis and delayed engagement in HIV care. The combination of pervasive stigma associated with MSM behavior and high rates of substance use hinders effective prevention efforts in this population, even as the prevalence of infection in Black MSM in some US cities approaches 50%. Reducing HIV-related disparities in MSM and among Black Americans are National HIV/AIDS Strategy priorities and are essential to the effort to control and prevent HIV/AIDS in the US.
The Lipid-lowering treatment is Ezetimibe+Simvastatin Drug Combination by oral administration. The patients in intervention group received simvastatin (10mg/day) + ezetimibe (20 mg/day) combined therapy for 12 month.
Systems and techniques for generating transforms from three-dimensional (3D) representations of oral care data are disclosed. The method involves receiving a first 3D representation of oral care data and providing it as input to a trained autoencoder network. The processing circuitry executes the trained autoencoder network to encode the first 3D representation into one or more latent space representations with a lower dimensionality. These latent space representations are then reconstructed into a second 3D representation that closely resembles the original input. The processing circuitry further provides the latent space representations to a trained machine learning (ML) model, distinct from the autoencoder network. By executing the trained ML model, a transform is generated. These systems and techniques enable the generation of accurate and efficient transforms from 3D representations of oral care data, facilitating improved analysis, diagnosis, and treatment planning in oral care applications.
INTRODUCTION: People with intellectual disability are at risk of poor physical and mental health. Risks to health are compounded by poor health literacy, that is, reduced capacity to access health services, respond quickly to changes in health status and navigate care pathways. Building health literacy skills is a strength-based way to increase health and optimise the use of healthcare services. The internet is a primary source of health information for many people, including people with intellectual disability and their families. This scoping review will aim to identify and collate online lay healthcare resources available to and developed for people with intellectual disability and their families and evaluate whether domains of health literacy are addressed.
METHODS AND ANALYSIS: This review will be reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping reviews guidelines. The proposed search strategy has three components. Resources will be identified by (1) reviewing disability organisation websites, (2) searching key disability and health terms in the Google search engine and (3) snowball sampling to identify additional resources through links in identified websites and resources. Resources will be selected if they are freely available, presented in or translatable into English, provide health information and are directed to people with intellectual disability or their family members. Extracted data will include descriptors of the source, format, area of health and targeted age range. Content relevant to domains of health literacy will be documented and gaps in available health information will be identified. Study findings will be presented in narrative, tabular and visual forms.
ETHICS AND DISSEMINATION: Ethical approval will not be sought because primary data will not be collected. The results will be disseminated in peer-reviewed literature, as conference presentations, as a synthesised resource for people with intellectual disability and their families and in summary documents for health service managers and policymakers.
Participants in this condition must indicate that they do not currently suffer from a mental health condition and score less than 20 on the Becks depression inventory. These participants will also undergo the motivate learning task and will study images associated with high and low rewards. After 24-hours participants will be tested on their memory for those images.
Constipation, abdominal cramps, weight loss, nausea, vomiting, oral ulceration, diarrhea, paralytic ileus, intestinal necrosis and/or perforation, and anorexia have occurred. Constipation may take the form of upper–colon impaction, and, on physical examination, the rectum may be empty. Colicky abdominal pain coupled with an empty rectum may mislead the physician. A flat film of the abdomen is useful in demonstrating this condition. All cases have responded to high enemas and laxatives. A routine prophylactic regimen against constipation is recommended for all patients receiving Vincristine Sulfate Injection.

Paralytic ileus (which mimics the "surgical abdomen") may occur, particularly in young pediatric patients. The ileus will reverse itself with temporary discontinuance of Vincristine Sulfate Injection and with symptomatic care.
Methods of assaying a breath sample from a subject for the presence of one or more toxins or toxin associated compounds are provided. In some embodiments, the one or more toxins or toxin associated compounds includes trichloroethylene (TCE) and/or one or more metabolites thereof. Embodiments of the methods further include providing a toxin exposure assessment that can be used to determine if the subject has been exposed to a toxin and to monitor changes in toxin exposure over time in the subject. In certain embodiments, a machine learning model may be used to determine if a subject has been exposed to one or more toxins. In some embodiments, the machine learning model may be trained by: analyzing breath samples from a plurality of subjects with a secondary electrospray ionization-high-resolution mass spectrometry analyzer to generate breath assay data; obtaining toxin exposure data for each subject; training a machine learning model to identify a relationship between the breath samples and toxin exposure using the breath assay data and the obtained toxin exposure data; and applying the trained machine learning model to breath assay data, different from the breath assay data used to train the model, to generate an exposure assessment regarding potential toxin exposure for a subject or subjects. In some embodiments, a health evaluation is generated for the subject using the toxin exposure assessment. Also provided are systems for use in practicing methods of the invention.
BACKGROUND: The severe postpartum hemorrhage (SPPH) leads to dangerous maternal conditions, and its rate is still increasing and the trend in related risk factors is changing. Placenta-related problems remain the high-risk factor for SPPH. The object is to investigate the prevalence and the risk factors of the severe postpartum hemorrhage in pregnant women with placenta previa or low-lying placenta.
METHOD: A retrospective analysis of pregnant women with placenta previa or low-lying placenta after 28 weeks gestation from May 2018 to May 2023 in the Peking Union Medical College Hospital was conducted. The primary outcome was severe postpartum hemorrhage defined as blood loss ≥ 1000 mL within 24 h of childbirth, or with signs or symptoms of low blood volume requiring transfusion of ≥ 4U of red blood cells. Univariate and multivariate logistic regression were used to identify potential risk factors of severe postpartum hemorrhage and receiver operating curve to evaluate the prediction performance.
RESULTS: Of the 14,964 women, 201 met the inclusive criteria. SPPH rate was 1.3% overall and 18.9% in women with placenta previa or low-lying placenta. Weight (aOR = 0.93, 95%CI 0.87-0.99), increta or percreta placenta (aOR = 7.93, 95%CI 2.53-24.77) were the risk factors. The area under the ROC curve was 0.69(95%CI 0.59-0.80) for increta or percreta placenta alone, and 0.72(95%CI 0.62-0.82) for the combination of times of cesarean sections and anterior placenta.
CONCLUSIONS: Placenta accreta spectrum was the key independent risk factor of SPPH in women with placenta previa or low-lying placenta. Antenatal risk assessment of SPPH in these population is highly desirable and optimal intervention could be planned.
Term newborns have anatomic and sonographic evidence of in utero estrogen exposure. Over the first six months to a year of life, as the influence of maternal hormone wanes, these findings recede. Soy infant formula contains large amounts of isoflavones (daidzein and genistein) that can occupy estrogen receptors and act as estrogens in the laboratory. A food substance with estrogen activity might prolong the effect of maternal hormones, or interfere with hormonal homeostasis in the child. This cross-sectional pilot study will be undertaken in order to establish methods for a future multi center study designed to assess the potential effects of soy formula on estrogen activity in infants. In this pilot study (SEAD 1), 156 examinations on full-term infants, ages 0-12 months and on one of three feeding regimens (soy formula, breast milk or cow's milk formula) will be completed to see if their exposure to soy estrogen compared to breast milk and non-soy formulas prolongs anatomical evidence of estrogen exposure and response. A schedule of visits for SEAD 1 is included in Appendix A. In addition to SEAD 1, two other cross-sectional studies (SEAD 2 and SEAD 3) will be undertaken to evaluate anatomical evidence by physical examination (SEAD 2) and assess the hormonal and biochemical status of full-term infants ages 0-12 months (SEAD 3). These studies will be conducted at Children's Hospital of Philadelphia (CHOP) in parallel with the SEAD 1 study. Further details of SEAD 2 and 3 will not be presented in this protocol. The purpose of the SEAD 1 pilot study is twofold. The first is to develop and finalize recruitment and collections procedures in preparation for a larger, comprehensive trial of biological response in children to soy formula with and without the estrogenic isoflavones. The second is to study the natural history of estrogen activity in infants on a variety of feeding regimens.
The invention belongs to natural organic chemistry field, relate to a kind of method of extracting general flavone from the wild Ranunculus sceleratus in Daxing'an Mountainrange, particularly relating to one utilizes ultrasonic wave extraction, ultra-filtration and separation and joins the new method of purifying general flavone with polyamide-macroreticular resin technology lotus root. Advantage of the present invention: extract convenient and swiftly, DNA purity is high, is applicable to large production. 1, using ultrasound ripple extractive technique, extracts active ingredients speed is fast, and content is high. 2, ultra-filtration and separation is carried out at normal temperatures, the problem of having avoided the active ingredient structural change that causes because of fuel factor and physiologically active to reduce. 3, polyamide-macroreticular resin lotus root joins technology, has further improved the purity of active ingredient, can make general flavone active ingredient activity higher. The present invention first makees solvent through ultrasonic pretreatment with ethanol, low temperature ultra-filtration and separation, more secondarily purified through polyamide-macroreticular resin, active ingredient general flavone purity brings up to 98.42%.
Keratosis in feet or plantar callosity is an injury caused by friction or pressure in certain location of the skin. This is a common problem faced by diabetic patients, which usually cause subcutaneous tissue maceration, which favors bacterial invasion. It is responsible for the development of abscesses and ulcers. Ulcer is the main cause of non-traumatic amputation of the feet in diabetic patients. Treatment with medicinal plants is an ancient practice. Brazil has one of the richest floras in the world. Brazilian Ministry of Health recommends the rational use of medicinal plants and encourage the use of this practice by health professionals.

The medicinal plant used in this study is a keratolytic agent, healing, emollient, bactericide and fungicide. The purpose of this study is evaluate the effectiveness of this medicinal plant in the treatment of keratosis in diabetic patients. This study will be controlled, randomized, comparative with standard drug and double-blind. Will be included in the study 90 adult diabetic patients type 1 or 2, with keratosis, both sexes, but do not show feet ulcerated lesions. Patients will be randomised controlled trials in three groups, with 30 people in each, which will receive topical treatment with medicinal plant (treatment group, TG), salicylate 10% (salicylate group, SG) and vaseline cream (control group, CG). The treatment will be once a day, for 30 consecutive days. Numerical scores will be made of the sites with keratosis and individual areas and global measures in the first, 30th days of treatment. The results obtained will be submitted to statistical comparison. This research will follow the standards set by resolution 466/12 of the National Health Council, the Vale do Sapucaí University, for research with human beings and will be conducted in accordance with the ethical recommendations of the Declaration of Helsinki.
OBJECTIVE: The aim of this study was to investigate the relationship between thyroid autoantibodies (TGAb and TPOAb) and X chromosome monosomy in the chorionic tissue of patients with missed early miscarriage.
METHODS: The baseline data, thyroid function, thyroid antibody and the chromosomes from the chorionic tissue of 228 patients with missed early miscarriage were examined.
RESULTS: (1) Among the 228 patients, 121 had a normal chromosome number, and 107 had an abnormal chromosome number. The majority of them were autosomal trisomy, of which trisomy 16 (40.19%) was predominant. Sex chromosome monosomy (28.04%) was secondary. (2) Among the 228 patients, 208 patients in this study had normal thyroid function (including 134 cases of negative thyroid antibodies and 74 cases of positive thyroid antibodies alone); 6 patients had abnormal thyroid function (including 2 cases of clinical hyperthyroidism, 3 cases of subclinical hypothyroidism, 1 case of hypothyroxinemia); and 14 patients had normal TSH and elevated T4 alone.(3) After exclusion of patients with thyroid function abnormalities, there were no significant differences in baseline data between the normal chromosome group and the abnormal chromosome group (P > 0.05). However, there was a significant difference in TGAb and TPOAb between the normal chromosome and abnormal chromosome group with 45, X karyotype, with a higher proportion of TGAb and/or TPOAb positivity in the 45, X karyotype group (P < 0.05). Additionally, compared to TGAb and/or TPOAb-positive patients, the risk of X chromosome monosomy was significantly reduced in TGAb and TPOAb-negative patients (P < 0.05). Moreover, both TGAb and TPOAb titer values in the X chromosome monosomy group were higher than those in the chromosomally normal group (P < 0.05).
CONCLUSION: There is a correlation between TGAb, TPOAb and X chromosome monosomy in the chorionic tissue of patients with missed early miscarriage, although the mechanism remains to be further investigated.
Emtricitabine: In long-term oral carcinogenicity studies of FTC, no drug-related increases in tumor incidence were found in mice at doses up to 750 mg/kg/day (26 times the human systemic exposure at the therapeutic dose of 200 mg/day) or in rats at doses up to 600 mg/kg/day (31 times the human systemic exposure at the therapeutic dose). 

FTC was not genotoxic in the reverse mutation bacterial test (Ames test), or the mouse lymphoma or mouse micronucleus assays. 

FTC did not affect fertility in male rats at approximately 140-fold or in male and female mice at approximately 60-fold higher exposures (AUC) than in humans given the recommended 200 mg daily dose. Fertility was normal in the offspring of mice exposed daily from before birth ( in utero) through sexual maturity at daily exposures (AUC) of approximately 60-fold higher than human exposures at the recommended 200 mg daily dose. 

Tenofovir Disoproxil Fumarate: Long-term oral carcinogenicity studies of TDF in mice and rats were carried out at exposures up to approximately 16 times (mice) and 5 times (rats) those observed in humans at the therapeutic dose for HIV-1 infection. At the high dose in female mice, liver adenomas were increased at exposures 16 times that in humans. In rats, the study was negative for carcinogenic findings at exposures up to 5 times that observed in humans at the therapeutic dose. 

TDF was mutagenic in the in vitro mouse lymphoma assay and negative in an in vitro bacterial mutagenicity test (Ames test). In an in vivo mouse micronucleus assay, TDF was negative when administered to male mice. 

There were no effects on fertility, mating performance, or early embryonic development when TDF was administered to male rats at a dose equivalent to 10 times the human dose based on body surface area comparisons for 28 days prior to mating and to female rats for 15 days prior to mating through day 7 of gestation. There was, however, an alteration of the estrous cycle in female rats.
A traditional Chinese herbal lotion preparation method for curing night sweat decubitus belongs to the technical field of traditional Chinese medicine preparation methods. At present, sulfonamides and antibiotics are generally adopted to cure the night sweat decubitus. If the sulfamethoxazole is adopted, gastrointestinal tract reaction, crystalluria, hematuresis, tetter, drug fever and leukopenia of patients are caused. The invention has the technical scheme that: figwort root, liriope spicata, radix asparagi, dendrobe, radix polygonati officinalis, lilium brownii, tortoise plastron, salvia miltiorrhiza, prepared rehmannia root, mulberry fructus mori, tylophora ovata root, obscured homalomena rhizome, toddalia asiatica, pawpaw, ficus simplicissima, cortex acanthopanacis, radix achyranthis bidentatae, zaocys dhumnades, blumea balsamifera, folium photiniae, serissa serissoides, fructus cannabis and liquorice are taken and placed into water to soak, then are decocted with soft fire to filter and remove dregs, and the decocted liquid medicine is the traditional Chinese herbal lotion for curing the night sweat decubitus. The invention has the advantages that: the prepared traditional Chinese herbal lotion has small toxic side effect and high curative ratio. The traditional Chinese medicines are applied at the same time, so the adverse effect, anaphylactic reaction and toxic reaction which are caused by Western medicines are avoided.
After patient has signed consent and had blood tests to ensure normal kidney function (BUN and Creatinine) as well as serum and urine pregnancy tests for females to ensure there is no pregnancy, the patient will have an Indirect MRA. The participant will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into participant's arm. The gadopentetate dimeglumine will be injected into the IV and the patient will be asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
Placebo injection 80ml/day. Placebo injection 40ml, diluted with 250ml of 0.9% sodium chloride injection, and then slowly intravenously infused twice a day.
The present disclosure provides a variant GABA A  receptor having a substitution of a wild-type amino acid with a cysteine. The present disclosure provides a photoregulator comprising: i) a linker; ii) a photoisomerizable moiety; and iii) a GABA A  receptor ligand. The present disclosure provides a light-regulated GABA A  receptor comprising: a) the variant GABA A  receptor; and b) the photoregulator covalently linked thereto. The present disclosure provides methods of modulating the activity of the light-regulated GABA A  receptor. The present disclosure provides a treatment method comprising administering the variant GABA A  receptor, or a nucleic acid encoding same; and administering the photoregulator. The present disclosure provides a transgenic non-human animal comprising in its genome a transgene encoding the variant GABA A  receptor.